Search clinical trials for: KUC 7483 CL

Total 825 results

Boehringer Ingelheim

Completed

Study to Determine Pharmacodynamic Effects and Pharmacokinetics of KUC 7483 CL in Patients With Spinal Cord Injury and Neurogenic Detrusor Overactivity

Spinal Cord Injuries
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of KUC 7483 CL Tablets in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of KUC 7483 Tablets in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Study to Investigate the Regional Drug Absorption of KUC-7483 CL Administered Via an Enterion™ Capsule Compared to an Immediate Release Formulation in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of KUC 7483 CL Tablets in Healthy Male Volunteers

Healthy
Kissei Pharmaceutical Co., Ltd.

Withdrawn

Long-term Safety and Efficacy of KUC-7483 in Patients With Overactive Bladder

Overactive Bladder

Japan
Kissei Pharmaceutical Co., Ltd.

Completed

A Phase II Study of KUC-7483 in Patients With Overactive Bladder

Overactive Bladder (OAB)

Japan
Boehringer Ingelheim

Completed

Study to Investigate the Effect of KUC 7483 CL on the QT/QTc Interval of the ECG in Comparison to Placebo and Moxifloxacin in Healthy Male and Female Volunteers

Healthy
Kissei Pharmaceutical Co., Ltd.

Completed

A Confirmatory Study of KUC-7483 in Patients With Overactive Bladder

Overactive Bladder

Japan
The Hospital for Sick Children
SickKids Foundation; The Cundill Centre for Child and Youth Depression

Unknown

Focused Suicide Prevention Strategy for Youth (FSPS)

Suicidal Ideation | Suicide, Attempted | Suicide

Canada
HeNan Sincere Biotech Co., Ltd

Completed

A Study of CL-197 Capsules in Healthy Participants

HIV-1

China
Boehringer Ingelheim

Completed

Investigation of Pharmacokinetics of BIBX 245 CL and Safety in Healthy Subjects

Healthy
Contour Research

Completed

Examination of Circumferential Reduction

Overweight or Obesity

United States
LG Chem

Active, not recruiting

A Phase I Clinical Trial to Investigate the Safety, Tolerability, and Pharmacokinetic Characteristics of TT-01025-CL in Healthy Subjects

Healthy

United States
HeartWorks, Inc.

Recruiting

Autologous Induced Pluripotent Stem Cells of Cardiac Lineage for Congenital Heart Disease

Congenital Heart Disease | Univentricular Heart | Heart Failure NYHA Class III | Heart Failure NYHA Class IV

United States
University of Vermont

Completed

Role of Magnesium Supplementation in the Treatment of Depression

Depression

United States
Medecins Sans Frontieres, Netherlands

Terminated

Effectiveness, Safety and Feasibility of HECT-CL, in Quetta, Pakistan (HECT-CL)

Cutaneous Leishmaniases

Pakistan
Boehringer Ingelheim

Completed

In Vivo Specificity of KUC 7483 CL Co-administered With Bisoprolol, Propranolol, and Acipimox in Healthy Male Subjects

Healthy
Federico II University

Withdrawn

Transvaginal Ultrasound Cervical Length Screening in Singleton Pregnancy Without Prior Spontaneous Preterm Birth

Preterm Birth

Italy
Boehringer Ingelheim

Completed

Single Increasing Doses of BIII 890 CL in Healthy Young Male Volunteers and in Healthy Elderly Male and Female Volunteers

Healthy
Boehringer Ingelheim

Terminated

Safety, Pharmacodynamics, and Pharmacokinetics After Multiple Different Oral Doses of BIIB 722 CL Tablets in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 187004 CL

Healthy

Germany
Octapharma

Completed

Study to Investigate Immunogenicity, Efficacy and Safety of Treatment With Human-cl rhFVIII

Severe Hemophilia A

United States, France, Canada, United Kingdom, India, Georgia, Moldova, Republic of, Poland, Ukraine
InQpharm Group

Completed

IQP-CL-101 in IBS Management

Irritable Bowel Syndrome

Germany
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Single Rising Inhaled Doses of BI 11054 CL Administered With the Respimat® in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Single Increasing Dose Followed by Maintenance Dose Tolerance Study of BIIR 561 CL in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Single Dose Followed by Maintenance Dose Tolerance Study of BIIR 561 CL in Healthy Elderly Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Oral BIBP 5371 CL in Healthy Male and Female Volunteers

Healthy
Mayo Clinic

Completed

Chronic Versus Intermittent Deep Brain Stimulation for Essential Tremor

Essential Tremor
Naval Medical Research Center

Unknown

Evaluation of a Diagnostic Device, CL Detect™ Rapid Test, for the Diagnosis of Cutaneous Leishmaniasis in Peru

Leishmaniasis, Cutaneous

Peru
Limacorporate S.p.a

Recruiting

H-35 CL TRAUMA Cemented Femoral Stem

Arthroplasty | Hip | Replacement

Italy
Boehringer Ingelheim

Terminated

Increasing Dose Tolerance Study in Healthy Male Volunteers After Administration of BIII 890 CL

Healthy
Boehringer Ingelheim

Completed

Safety and Tolerability of BIII 890 in Patients With Acute Ischemic Stroke

Stroke
Boehringer Ingelheim

Completed

Single Increasing Dose Tolerance Study in Healthy Male Volunteers of BIIR 561 CL

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 14332 CL Powder in Healthy Male Subjects

Healthy
Boehringer Ingelheim

Terminated

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 14332 CL as Tablet in Female and Male Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2
Boehringer Ingelheim

Terminated

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ESR 1150 CL in Healthy Subjects

Healthy
Shanghai Synergy Pharmaceutical Sciences Co., Ltd.

Not yet recruiting

Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Characteristics of HHT120 in Healthy Subjects (HHT120)

Healthy

China
Eli Lilly and Company
Loxo Oncology, Inc.

Not yet recruiting

A Study of [14C]-LOXO-783 in Healthy Adult Participants

Healthy

United States
Boehringer Ingelheim

Completed

Bioavailability, Pharmacokinetics and Safety of ESR 1150 CL in Healthy Adult Male Volunteers

Healthy
Charleston Laboratories, Inc

Completed

A Study in Opioid-Experienced, Non-Dependent Recreational Drug Users to Determine the Abuse Potential and Safety of CL-108 Tablets Administered Via the Oral Route

Pain | Nausea | Vomiting
St. Olavs Hospital
Rosenborgklinikken

Recruiting

Fixation of Patellar Tendon Grafts in Anterior Cruciate Ligament Reconstruction. Endobutton vs Metal Interference Screws

Knee Injuries

Norway
Boehringer Ingelheim

Completed

Influence of a Standardised High Fat Breakfast on the Bioavailability of BI 14332 CL in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Tolerability and Pharmacokinetics of BIIB 722 CL Drinking Solution and of BIIB 722 CL Filmcoated Tablet in Healthy Subjects

Healthy
Can-Fite BioPharma

Completed

A Phase 1/2 Study of CF102 in Patients With Chronic Hepatitis C Genotype 1

Chronic Hepatitis C

Israel
Health Discovery Labs
National Institute for Biomedical Imaging and Bioengineering (NIBIB); University... and other collaborators

Completed

Safety and Efficacy of the MyokinE100 (CL-EMS Alpha) Device in Inducing Visible Muscle Contraction in Healthy Volunteers

ICU Acquired Weakness

United States
Octapharma

Completed

Human Cell Line-derived Recombinant Factor VIII (Human-cl-rhFVIII) in Previously Untreated Patients

Severe Hemophilia A

Canada, United States, France, Spain, Ukraine, United Kingdom, Belarus, Georgia, Germany, India, Italy, Moldova, Republic of, Morocco, Poland, Portugal, Russian Federation, Slovenia
Octapharma

Completed

Assess the Safety and Efficacy of Individually Tailored Prophylaxis With Human-cl rhFVIII in Patients With Severe Haemophilia A

Severe Haemophilia A

Austria, United Kingdom, Bulgaria, Hungary, Germany, Poland, Romania, Slovakia
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Single Rising Doses of BIIB 722 CL and HPβCD in Young Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Metabolism and Pharmacokinetics of [14C]-DK-AH 269 CL in 12 Healthy Male Volunteers

Healthy

3

Subscribe